{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:50:22Z","timestamp":1776174622030,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2017G006021"],"award-info":[{"award-number":["2017G006021"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015507","name":"Shandong First Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81303013"],"award-info":[{"award-number":["81303013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023KY613"],"award-info":[{"award-number":["2023KY613"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116175","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T22:14:51Z","timestamp":1768601691000},"page":"116175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Secukinumab versus conventional immunotherapy in myasthenia gravis: A single-Center 24-week retrospective comparative study"],"prefix":"10.1016","volume":"172","author":[{"given":"Shuangmei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116175_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115872","article-title":"Myasthenia gravis: molecular mechanisms and promising therapeutic strategies","volume":"218","author":"Chen","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116175_bb0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14656566.2024.2332610","article-title":"Promising therapies for the treatment of myasthenia gravis","volume":"25","author":"Uysal","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116175_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.998217","article-title":"Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: a bibliometric analysis","volume":"13","author":"Su","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116175_bb0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116175_bb0025","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2026.116175_bb0030","article-title":"A phase 3 trial of Inebilizumab in generalized myasthenia gravis","volume":"8","author":"Nowak","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116175_bb0035","article-title":"Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116175_bb0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/PROM.S408175","article-title":"Impact of Ravulizumab on patient outcomes and quality of life in generalized myasthenia gravis","volume":"18","author":"Antozzi","year":"2023","journal-title":"Patient Relat Outcome Meas."},{"key":"10.1016\/j.intimp.2026.116175_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","article-title":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis","volume":"85","author":"Li","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.intimp.2026.116175_bb0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3389\/fneur.2020.00981","article-title":"From traditional to targeted immunotherapy in myasthenia gravis: prospects for research","volume":"11","author":"Mantegazza","year":"2020","journal-title":"Front. Neurol."},{"issue":"396","key":"10.1016\/j.intimp.2026.116175_bb0055","doi-asserted-by":"crossref","first-page":"578464","DOI":"10.1016\/j.jneuroim.2024.578464","article-title":"Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients","volume":"15","author":"Li","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2026.116175_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2018.11.005","article-title":"Il-23\/Th17 cell pathway: a promising target to alleviate thymic inflammation maintenance in myasthenia gravis","volume":"98","author":"Villegas","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2026.116175_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109693","article-title":"JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17\/Treg cells via regulating the JAK2\/STAT3-AKT\/mTOR signaling pathway","volume":"115","author":"Lu","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"14","key":"10.1016\/j.intimp.2026.116175_bb0070","article-title":"Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells","volume":"11","author":"Li","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2026.116175_bb0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","article-title":"Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity","volume":"96","author":"Aguilo-Seara","year":"2017","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.intimp.2026.116175_bb0080","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116175_bb0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjd\/ljac040","article-title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials","volume":"188","author":"Langley","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116175_bb0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2026.116175_bb0095","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116175_bb0100","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/02770903.2017.1283696","article-title":"Th-17 regulatory cytokines IL-21, IL-23, and IL-6 enhance neutrophil production of IL-17 cytokines during asthma","volume":"54","author":"Halwani","year":"2017","journal-title":"J. Asthma"},{"issue":"1","key":"10.1016\/j.intimp.2026.116175_bb0105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12967-023-03947-5","article-title":"Landscape analysis of m6A modification regulators related biological functions and immune characteristics in myasthenia gravis","volume":"21","author":"Li","year":"2023","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.116175_bb0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2026.116175_bb0115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"Immunotargets Ther."},{"issue":"16","key":"10.1016\/j.intimp.2026.116175_bb0120","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/1389450117666160307144027","article-title":"IL-17A and multiple sclerosis: Signaling pathways, producing cells and target cells in the central nervous system","volume":"17","author":"Kolbinger","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.intimp.2026.116175_bb0125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","article-title":"Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity","volume":"96","author":"Aguilo-Seara","year":"2017","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.intimp.2026.116175_bb0130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116175_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10072-015-2375-y","article-title":"Association study between IL-17A and IL-17F gene polymorphism and myasthenia gravis in Chinese patients","volume":"7","author":"Yue","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.intimp.2026.116175_bb0140","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS","volume":"11","author":"\u00c7ebi","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116175_bb0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1474-4422(21)00173-3","article-title":"Targeted molecular therapy for myasthenia gravis","volume":"20","author":"Suzuki","year":"2021","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116175_bb0150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","article-title":"Myasthenia gravis in 2025: five new things and four hopes for the future","volume":"272","author":"Binks","year":"2025","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116175_bb0155","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"26","key":"10.1016\/j.intimp.2026.116175_bb0160","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.116175_bb0165","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study","volume":"184","author":"Reich","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116175_bb0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116175_bb0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116175_bb0180","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:01:05Z","timestamp":1771513265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926000184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"alternative-id":["S1567576926000184"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116175","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secukinumab versus conventional immunotherapy in myasthenia gravis: A single-Center 24-week retrospective comparative study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116175"}}